Back to Treatments

Treatment

Durvalumab + Tremelimumab

1
Conditions
6
Trials
5,000
Participants
35%
Average Safety

Condition Evidence

Mesothelioma

6 trials · 5,000 participants

72% effectiveness · 35% safety
Durvalumab + Tremelimumab | DFDA